槲皮素对阿霉素所致肾病综合征大鼠的保护作用及机制

doi:10.3976/j.issn.1002-4026.2023.04.008

摘要/Abstract

摘要：

探讨槲皮素对肾病综合征模型大鼠的保护作用。选用SPF级雄性大鼠,单次尾静脉注射阿霉素6.5 mg/kg诱导肾病综合征大鼠模型,收集尿液测定24 h尿蛋白,检测血液生化血清总蛋白和白蛋白、总胆固醇、甘油三酯以及肾功能尿素氮和血肌酐的含量;HE染色观察肾组织病理变化;透射电镜观察肾足细胞超微结构变化;Western Blot检测肾组织Desmin、Nephrin和Synaptopodin的表达。结果表明:槲皮素能有效缓解肾病综合征模型大鼠的24 h尿蛋白,明显改善各项血液生化指标和肾功能损伤,减轻肾组织病理变化和肾足细胞的足突融合;同时,槲皮素可以降低Desmin的表达,并提高Nephrin和Synaptopodin的表达。槲皮素可有效治疗阿霉素诱导的肾病综合征模型大鼠,其可能通过稳定足细胞正常结构和功能发挥保护作用。

关键词: 槲皮素, 肾病综合征, 阿霉素, 蛋白尿, 足细胞

Abstract:

To investigate the protective effect of quercetin on nephrotic syndrome model rats. Specific Pathogen Free (SPF) male rats were selected, and a single tail vein injection of adriamycin 6.5 mg/kg was used to induce nephrotic syndrome in the rat model. Urine was collected to determine 24 h urine protein concentrations, and the contents of blood biochemical serum total protein and albumin, total cholesterol, triglyceride levels, and renal function markers (blood urea nitrogen and serum creatinine) were analyzed. The pathological changes in renal tissue were observed by hematoxylin and eosin staining. Transmission electron microscopy was used to examine the ultrastructure of renal podocytes. Western blot was used to detect the expression of desmin, nephrin, and synaptopodin in renal tissue. The results showed that quercetin effectively alleviated 24 h urinary protein in nephrotic syndrome model rats, significantly improved blood biochemical indicators and renal function injury, and alleviated pathological changes in renal tissue and the foot process fusion of renal podocytes. Simultaneously, quercetin can reduce the expression of desmin and increase the expression of nephrin and synaptopodin. Quercetin can effectively treat nephrotic syndrome model rats induced by adriamycin, and it may play a protective role by stabilizing the normal structure and function of podocytes.

Key words: quercetin, nephrotic syndrome, adriamycin, urine protein, podocyte

中图分类号:

R965.1

宋泽宇, 李振元, 潘涛, 孟祥婷, 李淞, 董海轮, 范华英. 槲皮素对阿霉素所致肾病综合征大鼠的保护作用及机制[J]. 山东科学, 2023, 36(4): 61-68.

SONG Zeyu, LI Zhenyuan, PAN Tao, MENG Xiangting, LI Song, DONG Hailun, FAN Huaying. Protective effect and mechanism of quercetin on adriamycin-induced nephrotic syndrome in rats[J]. Shandong Science, 2023, 36(4): 61-68.

图/表 6

表1

表2

表3

图1

图2

图3

参考文献 22

[1]	POLITANO S A, COLBERT G B, HAMIDUZZAMAN N. Nephrotic syndrome[J]. Primary Care, 2020, 47(4): 597-613. DOI: 10.1016/j.pop.2020.08.002. doi: 10.1016/j.pop.2020.08.002 pmid: 33121631
[2]	ENE-IORDACHE B, PERICO N, BIKBOV B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study[J]. The Lancet Global Health, 2016, 4(5): e307-e319. DOI: 10.1016/S2214-109X(16)00071-1. doi: 10.1016/S2214-109X(16)00071-1
[3]	ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: A cross-sectional survey[J]. Lancet (London, England), 2012, 379(9818): 815-822. DOI: 10.1016/S0140-6736(12)60033-6. doi: 10.1016/S0140-6736(12)60033-6
[4]	BRAD H, ROVIN. Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney International, 2019, 95(2): 281-295. DOI: 10.1016/j.kint.2018.11.008. doi: S0085-2538(18)30811-1 pmid: 30665569
[5]	RAVANI P, BERTELLI E, GILL S, et al. Clinical trials in minimal change disease[J]. Nephrology Dialysis Transplantation, 2017, 32(s1): i7-i13. DOI: 10.1093/ndt/gfw235. doi: 10.1093/ndt/gfw235
[6]	TULLUS K, WEBB H, BAGGA A. Management of steroid-resistant nephrotic syndrome in children and adolescents[J]. The Lancet Child & Adolescent Health, 2018, 2(12): 880-890. DOI: 10.1016/S2352-4642(18)30283-9. doi: 10.1016/S2352-4642(18)30283-9
[7]	CHEN Y Q, CHEN H Y, TANG Q Q, et al. Protective effect of quercetin on kidney diseases: From chemistry to herbal medicines[J]. Frontiers in Pharmacology, 2022, 13: 968226. DOI: 10.3389/fphar.2022.968226. doi: 10.3389/fphar.2022.968226
[8]	ZENG H M, GUO X P, ZHOU F, et al. Quercetin alleviates ethanol-induced liver steatosis associated with improvement oflipophagy[J]. Food and Chemical Toxicology: an International Journal Published for the British Industrial Biological Research Association, 2019, 125: 21-28. DOI: 10.1016/j.fct.2018.12.028. doi: 10.1016/j.fct.2018.12.028
[9]	GENG L L, LIU Z P, WANG S, et al. Low-dose quercetin positively regulates mouse healthspan[J]. Protein & Cell, 2019, 10(10): 770-775. DOI: 10.1007/s13238-019-0646-8. doi: 10.1007/s13238-019-0646-8
[10]	REYES-FARIAS M, CARRASCO-POZO C. The anti-cancer effect of quercetin: Molecular implications in cancer metabolism[J]. International Journal of Molecular Sciences, 2019, 20(13): 3177. DOI: 10.3390/ijms20133177. doi: 10.3390/ijms20133177
[11]	WANG X W, TIAN R M, YANG Y Q, et al. Tripterygium glycoside fraction n2 ameliorates adriamycin-induced nephrotic syndrome in rats by suppressing apoptosis[J]. Journal of Ethnopharmacology, 2020, 257: 112789. DOI: 10.1016/j.jep.2020.112789. doi: 10.1016/j.jep.2020.112789
[12]	LEE V W S, HARRIS D C H. Adriamycin nephropathy: A model of focal segmentalglomerulosclerosis[J]. Nephrology (Carlton, Vic), 2011, 16(1): 30-38. DOI: 10.1111/j.1440-1797.2010.01383.x. doi: 10.1111/j.1440-1797.2010.01383.x
[13]	ROSENBERG A Z, KOPP J B. Focal segmentalglomerulosclerosis[J]. Clinical Journal of the American Society of Nephrology, 2017, 12(3): 502-517. DOI: 10.2215/cjn.05960616. doi: 10.2215/cjn.05960616
[14]	包玉龙, 杨瑞, 刘禾, 等. 阿霉素大鼠肾病综合征模型最佳剂量的筛选[J]. 动物医学进展, 2018, 39(5): 61-63. DOI: 10.16437/j.cnki.1007-5038.2018.05.011. doi: 10.16437/j.cnki.1007-5038.2018.05.011
[15]	WU J B, YE S F, LIANG C L, et al. Qi-Dan Fang amelioratesadriamycin-induced nephrotic syndrome rat model by enhancing renal function and inhibiting podocyte injury[J]. Journal of Ethnopharmacology, 2014, 151(3): 1124-1132. DOI: 10.1016/j.jep.2013.12.028. doi: 10.1016/j.jep.2013.12.028
[16]	唐桂毅, 温和, 王晶晶, 等. 阿霉素肾病大鼠模型的评价研究[J]. 药物评价研究, 2020, 43(1): 66-71. DOI: 10.7501/j.issn.1674-6376.2020.01.011. doi: 10.7501/j.issn.1674-6376.2020.01.011
[17]	DOWNIE M L, GALLIBOIS C, PAREKH R S, et al. Nephrotic syndrome in infants and children: Pathophysiology and management[J]. Paediatrics and International Child Health, 2017, 37(4): 248-258. DOI: 10.1080/20469047.2017.1374003. doi: 10.1080/20469047.2017.1374003 pmid: 28914167
[18]	PRASAD R B, GROOP L. Precision medicine in type 2 diabetes[J]. Journal of Internal Medicine, 2019, 285(1): 40-48. DOI: 10.1111/joim.12859. doi: 10.1111/joim.12859 pmid: 30403316
[19]	ZHONG J Y, YANG H C, FOGO A B. A perspective on chronic kidney disease progression[J]. American Journal of Physiology Renal Physiology, 2017, 312(3): F375-F384. DOI: 10.1152/ajprenal.00266.2016. doi: 10.1152/ajprenal.00266.2016
[20]	MARTIN C E, JONES N. Nephrin signaling in the podocyte: An updated view of signal regulation at the slit diaphragm and beyond[J]. Frontiers in Endocrinology, 2018, 9: 302. DOI: 10.3389/fendo.2018.00302. doi: 10.3389/fendo.2018.00302 pmid: 29922234
[21]	GREKA A, MUNDEL P. Cell biology and pathology ofpodocytes[J]. Annual Review of Physiology, 2012, 74: 299-323. DOI: 10.1146/annurev-physiol-020911-153238. doi: 10.1146/annurev-physiol-020911-153238
[22]	YU S M W, NISSAISORAKARN P, HUSAIN I, et al. Proteinuric kidney diseases: A podocyte's slit diaphragm and cytoskeleton approach[J]. Frontiers in Medicine, 2018, 5: 221. DOI: 10.3389/fmed.2018.00221. doi: 10.3389/fmed.2018.00221

组别	24 h尿蛋白定量/mg
组别	第3 d	第7 d	第14 d	第21 d	第28 d
正常对照组	47.11±6.36	47.96±5.75	55.11±13.45	69.10±17.87	63.32±14.25
模型组	68.59±21.93	127.09±24.77^**	283.09±38.05^**	362.08±25.73^**	493.48±52.57^**
泼尼松组	74.04±21.93	129.08±24.77^**	195.56±38.05^##	226.77±25.73^##	235.98±52.57^##
25 mg/kg槲皮素组	80.24±18.42	127.74±25.41^**	246.89±26.43	336.82±17.50	409.22±49.13^##
50 mg/kg槲皮素组	75.02±17.71	124.49±19.16^**	213.84±37.87^##	271.87±47.38^##	310.37±51.92^##
100 mg/kg槲皮素组	73.32±20.80	121.39±11.09^**	203.41±40.17^##	224.42±54.35^##	228.40±46.20^##

组别	总蛋白质量浓度/ (g ·L^-1)	白蛋白质量浓度/ (g ·L^-1)	总胆固醇浓度/ (mmol ·L^-1)	甘油三酯浓度/ (mmol ·L^-1)
正常对照组	55.19±3.69	28.01±2.66	1.83±0.23	0.74±0.26
模型组	36.56±3.16^**	16.60±2.64^**	4.29±0.53^**	2.46±0.47^**
泼尼松组	51.86±2.47^##	24.96±1.84^##	2.73±0.68^##	1.25±0.34^##
25 mg/kg槲皮素组	39.59±4.99	15.56±2.98	4.40±0.47	2.44±0.39
50 mg/kg槲皮素组	51.47±2.78^##	21.98±3.25^#	3.34±0.48^##	1.91±0.23^#
100 mg/kg槲皮素组	53.00±6.94^##	26.10±1.81^##	2.41±0.84^##	1.63±0.25^##

组别	尿素氮浓度/(mmol ·L^-1)	血肌酐浓度/(μmol ·L^-1)
正常对照组	4.86±0.58	24.20±4.10
模型组	7.43±2.24^**	33.81±3.46^**
泼尼松组	5.12±1.23^#	26.18±3.44^##
25 mg/kg槲皮素组	7.18±1.41	31.41±5.63
50 mg/kg槲皮素组	6.32±1.16	30.31±3.26
100 mg/kg槲皮素组	5.08±0.82^##	24.94±4.66^##